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Abstract 19 
  20 
Aim To examine the effects of supplementing aspirin therapy with folic acid on vascular endothelial 21 
function among patients with type 2 diabetes. 22 
Methods This was a randomized open label crossover study. Fifteen patients with type 2 diabetes 23 
(group A) were first treated with 100 mg/day aspirin plus 20 mg/day folic acid for 1 week and then 24 
received aspirin alone during the second week. Conversely, 17 patients (group B) received 25 
aspirin alone during the first week and received the combination therapy during the second week. 26 
Fourteen patients (group C) received folic acid alone for one week. Flow mediated dilatation (FMD) 27 
was examined at baseline and after each treatment. 28 
Results In group A, the patients’ FMD levels increased from 3.7 ± 2.0 % to 7.2 ± 3.1 % during the 29 
first week and decreased to 5.9 ± 2.8 % after the second week. In group B, FMD levels increased 30 
from 5.1 ± 2.2 % to 6.8 ± 2.9 % during the first week and further increased to 9.0 ± 3.6 % after the 31 
second week. In group C, FMD levels increased from 5.2 ± 3.3 % to 6.9 ± 3.8 %. Concomitantly, 32 
serum homocysteine (Hcy) levels decreased during folic acid administration in group C, but not in 33 
groups A and B. Addition of folic acid did not significantly affect levels of interleukin-6 or high 34 
sensitivity C-reactive protein.  35 
Conclusion Supplementation of aspirin therapy with folic acid resulted in further improvement in 36 
endothelial function. The mechanism of the beneficial effect remains to be 37 
elucidated, although it is unlikely to be mediated by suppression of Hcy production or attenuation of 38 
chronic inflammation. 39 
 40 
Key words: Endothelial function, Flow-mediated dilatation (FMD), Aspirin, Folic acid, 41 
Homocysteine, Type 2 diabetes mellitus42 
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Introduction 43 
 44 
Type 2 diabetes is a major risk factor for cardiovascular diseases (CVD). Putative mechanisms of 45 
these vascular complications include inflammation of the vascular wall, oxidative stress, and the 46 
exacerbation of platelet aggregation because of hyperglycemia or other metabolic disorders of the 47 
diabetic state. Vascular endothelial dysfunction has been recognized as an early stage of 48 
arteriosclerosis because the endothelium is crucially important in maintaining both vascular tone and 49 
the normal structure of blood vessels [1–3]. One endothelium-derived vasoactive mediator of major 50 
importance is nitric oxide (NO), which is formed from the amino acid precursor L-arginine and 51 
endothelial nitric oxide synthase (eNOS) [4]. A deficiency in NO production may be involved in 52 
endothelial dysfunction [5].  53 
Platelet aggregation is enhanced in the diabetic state [6], and administration of low-dose aspirin has 54 
been recommended to prevent thrombosis in diabetic patients [7, 8]. Endothelial dysfunction can be 55 
improved by low-dose aspirin therapy, suggesting that platelets regulate vascular NO bioactivity [9]. 56 
Aspirin may also exert its beneficial effect on endothelial function through its anti-inflammatory 57 
properties [10, 11]. 58 
Folic acid, a water soluble vitamin, increases NO production by stabilizing tetrahydrobiopterin 59 
(BH4), a coenzyme for eNOS [12, 13]. The active form of folic acid, 5-methyltetrahydrofolate, has 60 
direct effects on the enzymatic activity of NO synthase both in recombinant eNOS and in cultured 61 
endothelial cells. Furthermore, folic acid reduces serum levels of homocysteine (Hcy), which is a 62 
potent excitatory neurotransmitter that binds to the Nmethyl-D-aspartate receptor and leads to 63 
oxidative stress, cytoplasmic calcium influx, cellular apoptosis, and endothelial dysfunction [14].     64 
Although low-dose aspirin therapy is recommended for individuals with cardiovascular risk factors, 65 
there is concern that administration of aspirin may reduce serum folic acid concentration by 66 
acceleration of urinary folic acid excretion [15]. Furthermore, aspirin is rapidly and irreversibly 67 
converted into salicylic acid, which inhibits production of tetrahydrofolate [16], an important methyl 68 
donor for remethylation of Hcy into methionine [17]. Thus, folic acid supplementation in aspirin 69 
therapy is expected to have an additive or a synergistic effect for prevention of CVD. In this study, 70 
we investigated the effects of the combination therapy of aspirin and folic acid on endothelial 71 
function and other biological variables among patients with type 2 diabetes. 72 
 73 
Subjects and methods 74 
 75 
Subjects 76 
 77 
We enrolled 46 patients with type 2 diabetes who had been admitted to Kurume University Hospital 78 
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for glycemic control (Table 1). Fifteen patients had been treated with sulfonylureas, 11 with 79 
metformin, 4 with pioglitazone, 14 with DPP-4 inhibitors, and 4 with insulin. The exclusion criteria 80 
included HbA1c[12.0 %, use of anti-platelet drugs, pregnancy and lactation, chronic inflammatory 81 
diseases, a recent acute infection, serum creatinine level [1 mg/dl, liver dysfunction (AST[40 IU/L or 82 
ALT[40 IU/L), known malignant diseases, current consumption of tobacco products, aspirin allergy, 83 
known history of CVD events, proliferative diabetic retinopathy, macro-albuminuria defined as a 84 
urinary albumin level [300 mg per day, and painful diabetic polyneuropathy. 85 
Appropriate dietary management was continued throughout the study period. Subjects were required 86 
to avoid any vigorous exercise. Written informed consent was obtained from all subjects. The study 87 
design was approved by the ethics committee of Kurume University School of Medicine and was 88 
conducted according to the principles outlined in the Declaration of Helsinki. 89 
 90 
Study design and materials 91 
 92 
After a period of stabilization of such metabolic parameters such as blood glucose, blood pressure, 93 
and serum lipids for 7 ± 2 days (mean ± SD), the subjects were randomly assigned to group A, group 94 
B, or group C (Fig. 1). The subjects of group A were given 20 mg folic acid (Foliamin
®
, Nihon 95 
Pharmaceutical, Tokyo, Japan) plus 100 mg aspirin (Bayaspirin
®
, Beyer, Leverkusen, Germany) 96 
once daily during the first week and then aspirin alone during the second week. The subjects of 97 
group B were administered aspirin during the first week and received the combination therapy 98 
during the second week. The subjects of group C were given 20 mg folic acid for 7 days. 99 
Flow-mediated dilatation (FMD), body weight, and blood pressure were measured after an overnight 100 
fast, and blood was collected at baseline and at the end of each week.  101 
 102 
Assessment of endothelial function  103 
 104 
Brachial artery FMD, a surrogate marker for vascular endothelial function, was measured by use of a 105 
vascular ultrasound system equipped with an edge-tracking system and a pulsed Doppler flow 106 
velocimeter (Unex, Nagoya, Japan) [18], at the supine position, before breakfast in a quiet room, in 107 
accordance with international guidelines [19]. In brief, after measurement of the diameter of the 108 
brachial artery at rest, the cuff was inflated to 200 mmHg for 5 min. After prompt cuff deflation, the 109 
diameter of the artery was monitored continuously. FMD levels were calculated as follows:  110 
 111 
FMD (%) = (maximum diameter－diameter at rest × 100 / diameter at rest. 112 
 113 
Blood sampling and measurements  114 
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 115 
Blood samples were obtained from the antecubital vein. Glucose, HbA1c, triglycerides (TG), 116 
low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) were 117 
measured in accordance with standard procedures. Folic acid and interleukin-6 (IL-6) levels were 118 
determined by chemiluminescence enzyme immunoassay. Hcy levels were measured by HPLC 119 
(Hitachi, Tokyo, Japan). 120 
 121 
Statistical analysis 122 
 123 
Statistical analysis was performed by use of JMP software version 10 (SAS Institute, Cary, NC, 124 
USA). To compare baseline values for each group, Student’s t-test was used for continuous variables 125 
after confirming the normality of the data distribution by use of the Shapiro–Wilk normality test. 126 
Categorical variables were analyzed by use of the chisquared test. Results for more than two groups 127 
were compared by one-way, repeated-measures analysis of variance (ANOVA). The effects of drugs 128 
on FMD values were compared by using the ratio of post-treatment FMD to baseline FMD. The 129 
ratios for FMD, serum levels of folic acid, hsCRP, and IL-6 were logarithmically transformed to 130 
achieve a normal distribution before applying the t-test. All data are presented as mean ± SD, and a 131 
p-value<0.05 was considered to be statistically significant. When data in three groups were 132 
compared, a significant p-value was<0.017 (Bonferroni correction). 133 
 134 
Results 135 
 136 
In group A, patients’ FMD levels increased from 3.7 ± 2.0 % to 7.2 ± 3.1 % (p = 0.001) during the 137 
first week and decreased to 5.9 ± 2.8 % (p = 0.02) after the second week (Fig. 2a). In group B, FMD 138 
levels increased from 5.1 ± 2.2 % to 6.8 ± 2.9 % (p = 0.001) during the first week and further 139 
increased to 9.0 ± 3.6 % (p = 0.004) after the second week (Fig. 2b). In group C, FMD levels 140 
increased from 5.2 ± 3.3 % to 6.9 ± 3.8 % (p = 0.016) (Fig. 2c). When the changes in FMD levels 141 
during the first week were expressed as the ratio of the post-treatment FMD to the baseline FMD, the 142 
aspirin monotherapy, the folic acid monotherapy, and the combination therapy resulted in 1.4 ± 143 
0.4-fold, 1.4 ± 0.4-fold, and 2.9 ± 3.1-fold increases, respectively (F = 5.63, p = 0.0068). Post-hoc 144 
analysis showed that the combination therapy resulted in greater improvement in FMD values than 145 
aspirin monotherapy (p = 0.013) and folic acid monotherapy (p = 0.026), although the latter was not 146 
statistically significant after the Bonferroni correction.  147 
For patients in group A, elevation of serum folic acid concentration was observed after the 148 
combination therapy and then a decline during the aspirin monotherapy. As expected, serum folic 149 
acid concentration for group B patients did not change during aspirin monotherapy but increased as a 150 
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result of the combination therapy. For group C patients elevation of serum folic acid concentration 151 
was observed after the folic acid monotherapy (Table 2).  152 
Among group C patients, serum Hcy concentration was reduced after the folic acid monotherapy. 153 
However, the difference was not significant by ANOVA in serum Hcy levels among baseline, aspirin 154 
monotherapy, and the combination of aspirin and folic acid in group A or group B (Table 2). 155 
Similarly, there was no significant difference in hsCRP or IL-6 among baseline, aspirin monotherapy, 156 
and combination therapy. 157 
 158 
Discussion 159 
 160 
Endothelial function of patients with type 2 diabetes is seriously degraded compared with that of 161 
healthy subjects [20, 21]. Aspirin inhibits platelet aggregation and improves endothelial function, 162 
and the effectiveness of low-dose aspirin in the prevention of CVD has been established. Folic acid 163 
supplementation reduces Hcy concentration, resulting in improvement of vascular NO 164 
bioavailability and overall endothelial function [22]. However, no investigation has been performed 165 
to assess the effects of a combination of aspirin and folic acid on vascular endothelial function. The 166 
rationale for combining folic acid and aspirin is that:  167 
 168 
1. aspirin induces a significant but reversible decrease in serum folic acid concentrations and 169 
a small increase in its urinary excretion [15]; and 170 
2. aspirin exerts its anti-inflammatory effects after its conversion into salicylic acid, which 171 
has greater antifolic acid activity than the parent compound [16]. 172 
 173 
Thus, folic acid supplementation in aspirin therapy may be a clinically useful strategy to prevent 174 
the impaired balance of this vitamin.  175 
We demonstrated in this study that 1-week combination therapy with low-dose aspirin and folic 176 
acid improved FMD of diabetic subjects more efficiently than either drug alone. FMD increased in 177 
the aspirin monotherapy group after addition of folic acid, but decreased in the combination therapy 178 
group after discontinuation of folic acid. The increases of FMD may be partially attributable to 179 
improvement of glycemic control. To minimize the effect of glycemic control improvement during 180 
the study period, this study was performed in a cross-over design. Reduction of FMD during the 181 
second week in group A clearly showed the beneficial effect of folic acid supplementation of aspirin 182 
monotherapy. In this study, folic acid levels were not reduced by aspirin treatment. The absence of 183 
effects on serum folic acid levels may be because aspirin was given in a small dose for a short period. 184 
Plasma levels of Hcy were significantly reduced by administration of folic acid in group C. It is 185 
widely accepted that increased plasma Hcy is associated with increased cardiovascular risk. 186 
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However, reduction of plasma Hcy may not be the mechanism by which folic acid supplementation 187 
of aspirin therapy further improved endothelial function, because no significant reduction was 188 
observed in groups A or B. Another possible mechanism is attenuation of inflammation, because 189 
chronic low-grade inflammation may be associated with endothelial dysfunction in diabetes. 190 
However, serum levels of hsCRP or IL-6 were not significantly different among baseline, aspirin 191 
monotherapy, and combination therapy, and folic acid monotherapy did not reduce hsCRP or IL-6 192 
levels.  193 
This study has several limitations. It was performed with a relatively small number of patients. 194 
However, a significant improvement of FMD was demonstrated after the folic acid supplementation. 195 
We calculated the sample number adequate for distinguishing the effect of folic acid on FMD with 196 
the standard deviations in this cross-over trial by using repeated-measures ANOVA with a 197 
Bonferroni correction [23]; a sample size of 32 was verified to be adequate to distinguish differences 198 
between this effect. Although the 1-week add-on treatment of folic acid proved beneficial for 199 
endothelial function, effects of longer-term administration are not guaranteed. Finally, patients with 200 
advanced diabetic complications were excluded because of concern about the effect of 201 
anticoagulation therapy, particularly retinal bleeding. These results are, therefore, limited to cases 202 
without advanced diabetic complications.  203 
In conclusion, folic acid supplementation of low-dose aspirin therapy resulted in further 204 
improvement of endothelial function among patients with type 2 diabetes. On the basis of these 205 
results, prospective studies with larger sample sizes for a longer period of time are needed to confirm 206 
the clinical relevance of folic acid supplementation of aspirin therapy for the prevention of CVD.  207 
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 289 
Figure legends 290 
 291 
Fig. 1  The study protocol.  Arrows indicate the times of FMD measurements and blood sampling. 292 
Fig. 2  Changes in FMD during the 2-week study period for patients of group A (a) and group B (b), 293 
and changes in FMD during the 1-week study period for patients of group C (c). Data are presented 294 
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as mean ± SD. 295 
Table 1. Clinical characteristics at baseline 
    All subjects group A group B group C P-value 
Number of patients 46 15 17 14 ― 
Gender (male/female)  20/26 7/8 5/12 8/6 0.29 
Habitual drinking (+/-) 15/31 5/10 3/14 7/7 0.17 
Age (years)    57±14   56±14 55±15 60±13 0.63 
BMI (kg/m2)  26.5±6.0   28.2±8.1 26.6±5.3 24.5±3.8 0.27 
Duration of diabetes (years)      8.9±8.2   7.6±7.7 9.9±2.4 7.6±6.2 0.41 
Systolic blood pressure (mmHg)    125±13   129±13 124±11 121±16 0.31 
Diastolic blood pressure (mmHg)       75±11 76±10 76±12 74±13 0.91 
RAS blockade (ACEI or ARB) (+/-) 6/40 2/13 1/16 3/11 0.46 
Statin (+/-) 13/33 3/12 4/13 6/8 0.35 
Fasting plasma glucose (mg/dL)  153±46 155±65 159±38 145±27 0.69 
HbA1c (%)  9.3±1.6 9.1±1.5 9.3±1.6 9.5±1.8 0.81 
LDL-C (mg/dL) 128±37 136±34 130±40 116±36 0.37 
HDL-C (mg/dL) 52±13 54±20 50±8 52±10 0.68 
TG (mg/dL) 146±61 154±77 141±54 142±54 0.81 
Creatinine (mg/dL)   0.68±0.26 0.71±0.41 0.66±0.15 0.68±0.14 0.82 
Folic acid (ng/mL) 8.1±3.5 7.6±4.0 7.8±2.8 9.1±3.7  0.49 
Homocysteine (μmol/L) 9.1±3.1 8.7±3.3 8.8±1.7 9.8±4.2  0.55 
hsCRP (mg/L) 1.63±2.24 1.86±1.82 1.51±1.97 1.53±3.0  0.9 
IL-6 (pg/mL) 3.3±3.8 2.7±1.8 4.3±5.7 2.7±2.0  0.39 
FMD (%) 4.7±2.6 3.8±2.1 5.1±2.2 5.2±3.4  0.25 
RAS: Renin-angiotensin system  ACEI: angiotensin converting enzyme inhibitor, ARB: angiotensin receptor blocker,                                                    
hsCRP: high-sensitivity C-reactive protein 
Data are presented as means±S.D. or numbers of patients.                                                                                                                                 
Most parameters were measured at hospitalization.     
One way ANOVA or Chi-square test was used for the comparison among the groups..    
Table 2. Changes of clinical parameters 
group A (n=15) group B (n=17) group C (n=14) 
    Baseline 
Aspirin plus     
folic acid                             
Aspirin   Baseline Aspirin 
Aspirin plus    
folic acid                            
  Baseline Folic acid                             
Folic acid (ng/mL) 7.6±3.8 118.8±101.0 ** # 23.6±5.4 ** 7.8±2.7 13.6±18.4 204±162.9 ** # 8.7±4.1 200.0±166.3 **  
Hcy (μmol/l) 8.7±3.2 6.7±1.6 6.9±1.7 8.8±1.6 8.9±2.0 7.9±1.7 9.9±4.2 8.6±2.9 * 
hsCRP (mg/L) 1.86±1.82 1.16±1.3 0.89±0.91 1.51±1.97 0.71±0.52 0.55±0.44 1.53±3.0 1.50±2.36 
IL-6 (pg/mL) 2.7±1.7 2.2±1.2 2.0±0.9 4.3±5.5 3.5±4.5 2.8±3.3 2.7±2.0 2.6±2.4 
Descriptions for each abbreviation are given in text.  
Data are presented as means±SD.                                                                                                                                                                                                                                                            
No significant difference was obtained in Hcy, hsCRP, or IL-6 among baseline, aspirin, and  aspirin plus folic acid by ANOVA.                   
*P<0.05, **P<0.001 vs. values at baseline.  #P<0.001 vs. values after aspirin mono-therapy.   
Aspirin 100mg + Folic acid 20mg Aspirin 100mg 
Aspirin 100mg + Folic acid 20mg Aspirin 100mg 
Group A 
(n=15) 
Group B 
(n=17) 
Week 1 Week 2 
Group C 
(n=14) Folic acid 20mg 
Figure 1. Sato, et al.   
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